Urovant Sciences News Releases http://ir.urovant.com/ Urovant Sciences News Releases en Urovant Sciences Presents Positive Pivotal Data for Vibegron During Plenary Session at American Urological Association Annual Meeting http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-presents-positive-pivotal-data-vibegron-during Pivotal Phase 3 EMPOWUR study met both co-primary endpoints, with significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p Mon, 06 May 2019 08:00:00 -0400 Urovant Sciences News Releases 6841 Urovant Sciences to Present Late-Breaking Data on Vibegron During Plenary Session at the American Urological Association Annual Meeting http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-present-late-breaking-data-vibegron-during Second abstract with data concluding vibegron does not inhibit CYP2D6, a common drug metabolism pathway, also accepted for podium presentation IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Apr. 29, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused Mon, 29 Apr 2019 08:00:00 -0400 Urovant Sciences News Releases 6836 Urovant Sciences Initiates Phase 3 Clinical Program with Vibegron for Overactive Bladder in Men with Benign Prostatic Hyperplasia http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-initiates-phase-3-clinical-program-vibegron-0 IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 27, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company developing and commercializing innovative therapies for urologic conditions, today announced that it has initiated COURAGE, an international Phase 3 Wed, 27 Mar 2019 08:00:00 -0400 Urovant Sciences News Releases 6826 Urovant Sciences Announces Positive Topline Results from Pivotal Phase 3 EMPOWUR Study of Vibegron in Patients with Overactive Bladder http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-announces-positive-topline-results-pivotal Vibegron met both co-primary endpoints demonstrating highly significant reduction in daily urge urinary incontinence episodes and micturitions, compared to placebo (p Tue, 19 Mar 2019 08:00:00 -0400 Urovant Sciences News Releases 6811 Urovant Sciences to Announce Topline Results from the EMPOWUR Phase 3 Study of Vibegron in Patients with Overactive Bladder http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-announce-topline-results-empowur-phase-3-study IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 18, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will host a conference call and live webcast Mon, 18 Mar 2019 16:05:00 -0400 Urovant Sciences News Releases 6801 Urovant Sciences to Present at the Cowen and Company 39th Annual Healthcare Conference http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-present-cowen-and-company-39th-annual IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 7, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing novel therapies for urologic conditions, today announced Chief Executive Officer Keith A. Thu, 07 Mar 2019 08:00:00 -0500 Urovant Sciences News Releases 6796 Urovant Sciences Appoints James Robinson to its Board of Directors http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-appoints-james-robinson-its-board-directors IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Mar. 6, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced James Robinson , President and Chief Operating Wed, 06 Mar 2019 08:00:00 -0500 Urovant Sciences News Releases 6786 Urovant Sciences Enters into Flexible Agreement for up to $100 Million Debt Financing with Hercules Capital http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-enters-flexible-agreement-100-million-debt IRVINE, Calif. & BASEL, Switzerland --(BUSINESS WIRE)--Feb. 22, 2019-- Urovant Sciences (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it has entered into a debt financing agreement Fri, 22 Feb 2019 17:20:00 -0500 Urovant Sciences News Releases 6761 Urovant Sciences Reports Financial Results for the Third Fiscal Quarter Ended December 31, 2018 http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-reports-financial-results-third-fiscal-quarter BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 13, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today reported financial results for the three months ended Wed, 13 Feb 2019 16:05:00 -0500 Urovant Sciences News Releases 6746 Urovant Sciences to Report 2018 Third Fiscal Quarter Financial Results http://ir.urovant.com/news-releases/news-release-details/urovant-sciences-report-2018-third-fiscal-quarter-financial BASEL, Switzerland & IRVINE, Calif. --(BUSINESS WIRE)--Feb. 6, 2019-- Urovant Sciences Ltd. (Nasdaq: UROV), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions, today announced it will report 2018 third fiscal quarter Wed, 06 Feb 2019 08:00:00 -0500 Urovant Sciences News Releases 6741